TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06801236: Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

Sponsor: Acerand Therapeutics (Hong Kong) Limited · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 88 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,539,384

Rescue Site Savings

+$1,005,312

Unlock Full NCT06801236 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06801236 Rescue Dossier →